• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Analysis Shows Only 14 Percent of U.S. COVID-19 Trials Completed

Analysis Shows Only 14 Percent of U.S. COVID-19 Trials Completed

April 19, 2021

A new analysis by the Clinical Trials Transformation Initiative (CTTI) shows just 14 percent of U.S. COVID-19 studies launched during the pandemic were completed. While the remaining 86 percent of trials remain active, many have either not reported results or will never be completed.

The analysis, which was based on a final cohort of 450 studies and excluded COVID-19 vaccines, found that only 61 studies with a combined 24,753 participants had reached their end state, meaning they were either completed, suspended or terminated, by the end of 2020.

The remaining 389 studies, with a combined 474,096 participants, remain active. The analysis found that results were available from 44 studies — 21 of which had reached their end state and 23 of which were still active.

CTTI found that of the 450 studies launched, 214 were being funded by the industry, but 160 had no external source of funding at all. Of the remainder, 49 had other sources of funding and 27 were funded by the NIH.

Of the 61 completed studies, 25 were funded by industry, 25 had no external source of funding, six had other sources of funding and five were financially supported by the NIH. The 389 studies still active included 189 from industry, followed by 135 with no external funding. Forty-three active studies had other sources of funding and 22 NIH studies are still continuing.

The analysis also found that a little more than half, 51.1 percent, of the 450 studies had multiple sites. Of the 160 studies that had no external source of funding, only 36, or 22.5 percent, had more than one site.

Studies of immunomodulators made up 159, or 35.3 percent, of the 450 COVID-19 studies launched during the pandemic, while 112 interventions labeled “Other” made up 24.9 percent. There were 103 antiviral studies that accounted for 22.9 percent of the total, and 52 neutralizing antibody therapy studies that made up 11.6 percent. Studies involving anti-thrombotic therapy (29 total), cell and gene therapy (25), SARS-CoV-2 neutralizing antibodies (19), steroids (8) and nonCOVID vaccines (2) were also launched.

According to the methodology, CTTI considered studies registered in the ClinicalTrials.gov database that were launched in 2020 and had at least one site in the U.S.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing